

## Theralase™ Retains Leading Investor Relations Firm

### For Immediate Release

TORONTO, September 12 - Theralase™ Technologies Inc. (TSX-V: TLT & OTC BB: TLTF) ("Theralase"), a designer, manufacturer and distributor of therapeutic medical laser systems, announced today that it has retained The Equicom Group Inc. ("Equicom") to provide the Company with strategic investor relations and financial communications services.

Equicom provides strategic communications services to approximately 100 public companies across a diverse range of industries. Under the terms of the agreement, Theralase will pay Equicom a monthly retainer fee of \$5,000 for professional services. The initial contract term is 6 months. Neither Equicom nor any of its principals has an ownership interest, directly or indirectly, in Theralase or its securities, and the Company has not granted Equicom or its principals any right to acquire such an interest. Equicom, a wholly-owned subsidiary of TSX Group Inc., is headquartered in Toronto, with offices in Montreal and Calgary. For further information, please visit [www.equicomgroup.com](http://www.equicomgroup.com).

### About Theralase Technologies Inc.

Theralase Technologies Inc. designs, manufactures and distributes patented, super-pulsed laser technology used in a wide range of bio-stimulation and bio-destruction clinical applications. The Theralase technology platform targets several diverse healthcare sectors -- firstly, for non-invasive pain management and clinical therapy, in hundreds of neural muscular skeletal conditions, including arthritis -- secondly, to bio-stimulate and accelerate wound care and healing, including; bone fracture regeneration and osteoarthritic conditions -- and thirdly, combining photodynamic compounds with super-pulsed, biofeedback laser technology to attack specifically targeted cancers, bacterium, viruses and fat cells.

For a complete profile of Theralase Technologies Inc. and its products visit the corporate website, [www.theralase.com](http://www.theralase.com), and the regulatory website at [www.sedar.com](http://www.sedar.com).

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the contents of this release.

For further information: Roger Dumoulin-White, Theralase Technologies Inc., President & CEO, (416) 447-8455, [rwhite@theralase.com](mailto:rwhite@theralase.com); Vanessa Beresford, The Equicom Group Inc., (416) 815 0700, ext 227, [vberesford@equicomgroup.com](mailto:vberesford@equicomgroup.com)